AbbVie Inc (ABBV)vsNational HealthCare Corporation (NHC)
ABBV
AbbVie Inc
$257.60
-2.24%
HEALTHCARE · Cap: $447.53B
NHC
National HealthCare Corporation
$229.00
+0.15%
HEALTHCARE · Cap: $3.43B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4017% more annual revenue ($62.82B vs $1.53B). NHC leads profitability with a 8.1% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.42. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
NHC
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.8%
Fair Value
$147.26
Current Price
$257.60
$110.34 premium
Margin of Safety
-71.1%
Fair Value
$98.39
Current Price
$229.00
$130.61 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Moderate valuation
2.2% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.
Bull Case : NHC
The strongest argument for NHC centers on Debt/Equity, Altman Z-Score, PEG Ratio. PEG of 0.82 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 124.8x leaves little room for execution misses.
Bear Case : NHC
The primary concerns for NHC are P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
NHC carries more volatility with a beta of 0.64 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 51/100) and 12.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
National HealthCare Corporation
HEALTHCARE · MEDICAL CARE FACILITIES · USA
National HealthCare Corporation operates, manages, and provides services to skilled nursing facilities, assisted living facilities, independent living facilities, home health programs, and a behavioral health hospital. The company is headquartered in Murfreesboro, Tennessee.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?